Clinical Trials
10 trialsNCT01187810 2022-03-31
Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL
South Plains Oncology Consortium
Phase 1 Terminated
NCT01553071 2022-03-31
Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies
South Plains Oncology Consortium
Phase 1 Terminated
NCT02163356 2022-03-31
SPOC2013-001
South Plains Oncology Consortium
Phase 1 Terminated
NCT01535157 2020-08-27
Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
South Plains Oncology Consortium
Phase 1/2 Terminated
NCT00102635 2018-11-15
4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01479192 2018-11-07
Fenretinide in Healthy Young Women at Genetic and Familial Risk
European Institute of Oncology
Phase 3 Terminated
NCT00288067 2014-10-06
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00017134 2013-06-10
Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk
GOG Foundation
Phase NA Terminated
NCT00075491 2013-01-24
Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00003223 2012-07-24
SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth
SWOG Cancer Research Network
Phase 2 Terminated